Lungpacer Medical, Inc.
Lungpacer Medical is dedicated to developing minimally invasive neurostimulation technologies to help patients wean off mechanical ventilation and breathe independently. Their flagship product, the AeroPace System, is designed to stimulate the nerves that activate and exercise the diaphragm, aiming to rebuild diaphragm strength and facilitate faster ventilator weaning. The company is also developing the AeroNova System, which utilizes continuous diaphragm stimulation to reduce ventilator-induced injury. Lungpacer's mission is to improve patient outcomes, reduce healthcare costs, and transform the future of ventilation through innovative neurostimulation therapies.
Industries
Nr. of Employees
medium (51-250)
Lungpacer Medical, Inc.
Suite 130, 601 W Cordova Street, Vancouver, B.C. V6B 1G1, Canada
Patents
Apparatus and methods for assisted breathing by transvascular nerve stimulation
US-12239838-B2
View DetailsSystems and related methods for optimization of multi-electrode nerve pacing
US-12172020-B2
View DetailsDevices and methods for prevention, moderation, and/or treatment of cognitive injury
US-12029901-B2
View Details
Apparatus and methods for assisted breathing by transvascular nerve stimulation
US-12239838-B2
View DetailsSystems and related methods for optimization of multi-electrode nerve pacing
US-12172020-B2
View DetailsDevices and methods for prevention, moderation, and/or treatment of cognitive injury
US-12029901-B2
View DetailsProducts
Catheter-based diaphragm neurostimulation system (FDA PMA approved for ventilator weaning support)
A system composed of a bedside stimulation console and a multi-lumen transvenous catheter with embedded electrodes designed to deliver periodic phrenic nerve stimulation to strengthen the diaphragm and support weaning in adult patients on prolonged mechanical ventilation. Reported regulatory approval includes U.S. FDA premarket approval for specified adult weaning indications.
Investigational continuous diaphragm stimulation system (in clinical investigation)
An investigational catheter-based system and software designed to provide continual, ventilation-synchronized diaphragm stimulation aimed at achieving physiologic breathing patterns and potentially mitigating ventilator-induced injury; currently evaluated under investigational device protocols.
Catheter-based diaphragm neurostimulation system (FDA PMA approved for ventilator weaning support)
A system composed of a bedside stimulation console and a multi-lumen transvenous catheter with embedded electrodes designed to deliver periodic phrenic nerve stimulation to strengthen the diaphragm and support weaning in adult patients on prolonged mechanical ventilation. Reported regulatory approval includes U.S. FDA premarket approval for specified adult weaning indications.
Investigational continuous diaphragm stimulation system (in clinical investigation)
An investigational catheter-based system and software designed to provide continual, ventilation-synchronized diaphragm stimulation aimed at achieving physiologic breathing patterns and potentially mitigating ventilator-induced injury; currently evaluated under investigational device protocols.
Services
Design and sponsorship of multi-center preclinical and clinical studies (early feasibility, randomized controlled, and pivotal trials) evaluating catheter-based diaphragm neurostimulation; operational collaboration with international clinical sites and investigators.
Design and sponsorship of multi-center preclinical and clinical studies (early feasibility, randomized controlled, and pivotal trials) evaluating catheter-based diaphragm neurostimulation; operational collaboration with international clinical sites and investigators.
Expertise Areas
- Diaphragm neurostimulation therapy development
- Transvenous catheter-based device engineering
- Critical care clinical trial design and multi-center execution
- Regulatory strategy and approvals for high-risk medical devices
Key Technologies
- Transvenous phrenic nerve stimulation
- Multi-lumen central venous catheter with integrated electrodes
- ECG-guided catheter placement
- Automated electrode mapping algorithms
News & Updates
Lungpacer has announced its 150th patent, demonstrating its commitment to revolutionizing mechanical ventilation and serving millions of patients annually.
Timothy Alexander reports on Lungpacer’s upcoming research presentations at the American Thoracic Society (ATS) 2025 conference in San Francisco.
Lungpacer plans to double its workforce and raise investment capital to commercialize its FDA-approved AeroPace System.
Lungpacer received an FDA investigational device exemption (IDE) to begin clinical trials for its AeroNova System.
Lungpacer actively participates in major medical conferences to showcase its research and technology.
A multi-center trial demonstrates AeroPace strengthens the diaphragm, weans more patients from ventilation, and reduces ventilator time.
Lungpacer has announced its 150th patent, demonstrating its commitment to revolutionizing mechanical ventilation and serving millions of patients annually.
Timothy Alexander reports on Lungpacer’s upcoming research presentations at the American Thoracic Society (ATS) 2025 conference in San Francisco.
Lungpacer plans to double its workforce and raise investment capital to commercialize its FDA-approved AeroPace System.
Lungpacer received an FDA investigational device exemption (IDE) to begin clinical trials for its AeroNova System.
Lungpacer actively participates in major medical conferences to showcase its research and technology.
A multi-center trial demonstrates AeroPace strengthens the diaphragm, weans more patients from ventilation, and reduces ventilator time.